Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori

PHASE3CompletedINTERVENTIONAL
Enrollment

561

Participants

Timeline

Start Date

October 30, 2022

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

Tegoprazan

tegoprazan-containing bismuth quadruple therapy or Esomeprazole-containing bismuth quadruple therapy; Route of administration: oral;

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

INDUSTRY